Get the Stockscreener App
2.73
0.36%
-0.01
After Hours:
2.73
Taysha Gene Therapies Inc stock is traded at $2.73, with a volume of 1.27M.
It is down -0.36% in the last 24 hours and up +18.18% over the past month.
Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes, TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.
See More
Previous Close:
$2.74
Open:
$2.72
24h Volume:
1.27M
Relative Volume:
0.34
Market Cap:
$586.03M
Revenue:
$12.87M
Net Income/Loss:
$-114.34M
P/E Ratio:
-3.1575
EPS:
-0.8646
Net Cash Flow:
$-79.23M
1W Performance:
+5.41%
1M Performance:
+18.18%
6M Performance:
+82.00%
1Y Performance:
+23.53%
1-Day Range:
$2.65
$2.79
1-Week Range:
$2.525
$2.91
52-Week Range:
$1.05
$3.31
Taysha Gene Therapies Inc Stock (TSHA) Company Profile
Name
Taysha Gene Therapies Inc
Sector
Industry
Phone
(214) 612-0000
Address
3000 PEGASUS PARK DRIVE, DALLAS
Compare TSHA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TSHA
Taysha Gene Therapies Inc
|
2.73 | 716.59M | 12.87M | -114.34M | -79.23M | -0.8646 |
|
VRTX
Vertex Pharmaceuticals Inc
|
456.87 | 120.48B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
545.46 | 59.88B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
392.24 | 44.31B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
670.33 | 36.65B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
301.13 | 32.46B | 3.81B | -644.79M | -669.77M | -6.24 |
Taysha Gene Therapies Inc Stock (TSHA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-11-25 | Initiated | BofA Securities | Buy |
| Jun-27-24 | Initiated | BMO Capital Markets | Outperform |
| Apr-09-24 | Initiated | Piper Sandler | Overweight |
| Feb-01-23 | Downgrade | Jefferies | Buy → Hold |
| Jan-27-23 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Nov-09-22 | Downgrade | Goldman | Buy → Neutral |
| Mar-09-22 | Initiated | Robert W. Baird | Outperform |
| Mar-01-22 | Initiated | Wells Fargo | Overweight |
| Feb-18-22 | Initiated | SMBC Nikko | Outperform |
| Dec-16-21 | Initiated | Guggenheim | Buy |
| Jul-16-21 | Initiated | Needham | Buy |
| Jun-24-21 | Initiated | Truist | Buy |
| Jun-15-21 | Initiated | BTIG Research | Buy |
| Jun-09-21 | Initiated | Wedbush | Outperform |
| Jun-08-21 | Initiated | JMP Securities | Mkt Outperform |
| May-19-21 | Initiated | Cantor Fitzgerald | Overweight |
| May-11-21 | Resumed | Jefferies | Buy |
| Feb-24-21 | Initiated | William Blair | Outperform |
| Jan-05-21 | Initiated | Oppenheimer | Outperform |
| Oct-19-20 | Initiated | Chardan Capital Markets | Buy |
| Oct-19-20 | Initiated | Goldman | Buy |
| Oct-19-20 | Initiated | Jefferies | Buy |
| Oct-19-20 | Initiated | Morgan Stanley | Overweight |
View All
Taysha Gene Therapies Inc Stock (TSHA) Latest News
Needham Maintains a Buy on Taysha Gene Therapies (TSHA), Keeps PT at $8 - Insider Monkey
14 Best Biotech Penny Stocks to Buy Right Now - Insider Monkey
10 Penny Stocks That Will Skyrocket - Insider Monkey
Will Taysha Gene Therapies Inc. stock benefit from AI tech trendsFree Smart Money Stock Analysis - beatles.ru
How did TSHA's Q1 2024 EPS surprise impact short-term traders? - AInvest
What institutional investors are buying Taysha Gene Therapies Inc. stockExponential return rates - jammulinksnews.com
Why is Taysha Gene Therapies Inc. stock attracting strong analyst attentionCapitalize on fast-moving market trends - jammulinksnews.com
Certain Options of Taysha Gene Therapies, Inc. are subject to a Lock-Up Agreement Ending on 28-JUL-2025. - MarketScreener
What are the technical indicators suggesting about Taysha Gene Therapies Inc.Unlock powerful trading tools for investors - jammulinksnews.com
Is Taysha Gene Therapies Inc. stock overvalued or undervaluedFree Advanced Stock Screener Access - jammulinksnews.com
What are analysts’ price targets for Taysha Gene Therapies Inc. in the next 12 monthsFree Stock Chart Pattern Guide - jammulinksnews.com
Is it the right time to buy Taysha Gene Therapies Inc. stockUnlock powerful trading strategies for gains - jammulinksnews.com
How Taysha Gene Therapies Inc. stock performs during market volatility200 Percent Profit Outlook - metal.it
Taysha Gene Therapies Inc. Stock Analysis and ForecastConsistently superior profits - PrintWeekIndia
Is Taysha Gene Therapies Inc. a good long term investmentLightning-fast growth - PrintWeekIndia
Can Taysha Gene Therapies Inc. stock recover from recent declineConsistently profitable trades - jammulinksnews.com
What analysts say about Taysha Gene Therapies Inc. stockFree Capital Growth Strategies - PrintWeekIndia
Rett bet set includes Neurogene, Taysha gene therapies - BioWorld MedTech
What drives Taysha Gene Therapies Inc. stock priceUnrivaled growth potential - Autocar Professional
Leigh Syndrome Market Research Report 2025-2035 | Competitive Analysis of PTC Therapeutics, Pharming Group, Edison Pharmaceuticals, Taysha Gene Therapies, and Thiogenesis Therapeutics - Yahoo Finance
Taysha Gene Therapies, Inc. (NASDAQ:TSHA) Receives $8.17 Consensus PT from Analysts - Defense World
Taysha Gene Therapies (TSHA) Moves to Buy: Rationale Behind the Upgrade - Yahoo Finance
Why Taysha Gene Therapies Inc. stock attracts strong analyst attentionVerified Return Tips - Newser
What makes Taysha Gene Therapies Inc. stock price move sharplyFree Long-Term Wealth Growth Plan - Newser
Taysha Gene Therapies Inc Stock (TSHA) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.43%
2.00%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):